FT836 CAR T-cell Therapy

Phase I Study of FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

More Information

Trial Status
Not yet accepting
Trial Phase
Phase 1
Enrollment
12 patients (estimated)
Tags
CAR T Cell (Allogeneic), T Cell (Allogeneic), MICB, MICA
Trial Type
Treatment
Last Update
SparkCures ID
2204
NCT Identifier
NCT07221032

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.